AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

8 stories found

A clinician compares overlapping prostate-cancer risk maps before a radiotherapy decision.
Social good & healthSweden+2 clusters01

A prostate-cancer AI reordered risk, but has not proved better care

A better-looking risk chart is not yet a better treatment for a patient. A new Scientific Reports study tested a previously developed multimodal AI model on 353 people receiving radiotherapy for localized prostate cancer in the STHLM3 cohort. The model combined clinical features and biopsy-slide information and produced a different risk ordering from the European Association of Urology categories. For biochemical recurrence, its concordance index was 0.65 versus 0.60 for the EAU scheme. The reported difference did not meet conventional statistical significance, with p = 0.09. Comparisons for high-risk biochemical recurrence and prostate-cancer-specific mortality were also not statistically significant. The study did find exploratory variation inside the conventional high-risk group: a subset labeled low-risk by AI had no observed biochemical recurrence over ten years, while another subset did substantially worse. That may be worth pursuing, but it is not a license to de-escalate therapy today. The threshold was determined within this radiotherapy cohort, events were limited, and the population was linked to the same broader research setting used during model development. Independent external validation and prospective tests of treatment decisions are still needed. A patient might reasonably ask, 'Would this change what my doctor does, and would that help me?' The current paper cannot answer that outcome question. Its real contribution is a testable hypothesis about who needs more or less treatment, with a clear warning that promising stratification must survive clinical trials before becoming a care rule.

7 min
A researcher examines imaging slices with warm brown-fat signals while a separate mouse study remains in the background.
Social good & healthUnited States+2 clusters02

AI helped map brown fat in thousands of scans. The drug clue is not a cure.

An existing blood-pressure medicine has become an intriguing candidate in brown-fat research, but the evidence has not crossed into a human treatment claim. In a peer-reviewed Nature study, researchers analyzed imaging and records from 101,243 patients at a large cancer center. Brown fat, which spends energy producing heat, was associated with lower prevalence of several cardiovascular and psychiatric diagnoses. Machine learning allowed the team to semi-automatically quantify brown-fat activity in roughly 8,700 patients. Higher activity, particularly in one underarm depot, correlated with lower odds of cardiometabolic disease and a healthier distribution of white fat. Medication records then pointed to a class of blood-pressure drugs. Follow-up tests found that losartan increased brown-fat cell activity and energy expenditure in mice. That sequence matters: the AI analysis helped move from a broad clinical pattern to a specific, experimentally testable mechanism. It also sets a firm boundary. These patients were not randomized to change brown-fat activity; they were drawn from a cancer center; and the losartan result was not a trial showing improved human outcomes. The NIH describes it as a possible route to future drug repurposing, not a current indication. Patients should not alter medication because of a headline. The next evidence should be replication in other populations and prospective testing that measures patient outcomes, dosage and adverse effects. The real success of AI here is accelerating a scientific question without pretending the answer is finished.

6 min
A sterile robotic wet lab connects an AI experiment planner to pipettes and culture plates while a scientist holds a physical safety interlock over one amber anomaly.
Social good & healthUnited States+4 clusters03

Anthropic builds a wet lab as it explores AI-directed biology

Anthropic has confirmed that it is establishing a wet laboratory in the San Francisco Bay Area and exploring whether Claude can direct robotic equipment with limited human intervention. The company's life-sciences leadership told Reuters that biology ultimately requires experiments in the physical world and that human oversight remains essential. Anthropic says the laboratory is not specifically a drug-discovery facility, has not disclosed its exact work, and is not running clinical trials. Its broader ambitions include tools for rare, neglected, and currently difficult-to-treat conditions, while its Model Hardware Standard is intended to help AI systems communicate with laboratory equipment. The company also acquired Coefficient Bio; Reuters reported a roughly $400 million stock price based on a source, but Anthropic confirmed the acquisition without confirming the amount. The opportunity is substantial: an AI system that can design an experiment, interpret results, and revise the next run could compress research cycles. The risk also changes when text output becomes physical action. A hallucinated protocol, contaminated sample, unsafe reagent combination, or overconfident biological inference can propagate through automation before a person notices. Governance should therefore attach to the closed loop, not only the model. Every AI-directed experiment needs bounded hardware permissions, validated protocols, chain-of-custody logs, biological screening, anomaly detection, and a human stop authority that remains effective when the system proposes the next step faster than a scientist can review it.

8 min
A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters04

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
Six protein biomarker dials converge on an experimental molecule above a lung scan while an unfinished trial path continues into shadow.
Social good & healthGlobal+2 clusters05

An AI-discovered lung drug shifted six aging clocks, not human lifespan

An experimental drug developed with AI has produced a result that is scientifically interesting and extremely easy to oversell. Rentosertib was designed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. Its target was identified with AI and its molecule was generated through an AI-driven discovery platform. Researchers analyzed protein data from 42 patients in a 12-week phase 2a trial and applied six independently developed proteomic aging clocks. All six estimated a reduction in predicted biological age among treated patients. Earlier trial results also showed a promising dose-related improvement in forced vital capacity, an important lung-function measure. Agreement across multiple clocks makes the signal less likely to be an artifact of one aging model. It does not prove that the drug extends life, reverses aging throughout the body, or is safe and effective as a longevity treatment. The cohort was small, the follow-up was short, the participants had a serious age-related disease, and improving inflammation or fibrosis can change proteins used by aging clocks. The Nature Biotechnology paper also discloses that several authors work for the company developing the drug and that its company leader is an author. The responsible interpretation is neither miracle nor dismissal. This is a hypothesis-generating biomarker result attached to a candidate that has advanced in clinical development. Larger, longer, independently scrutinized trials should prespecify aging endpoints and connect them with functional outcomes, safety, disease progression, and eventually survival. AI accelerated the discovery path. Biology still decides whether the claim survives.

5 min
A precise national-policy dossier shows AI benefits passing through signed safety, worker-support, and human-control checkpoints before a scale gate opens.
Law & informationSingapore+4 clusters06

Singapore puts human control at the center of national AI adoption

Singapore’s 2026 National Day Rally framed AI adoption as a national bargain rather than an unrestricted technology race. The prime minister highlighted AI agents for small businesses, personalized exercise plans, breast-cancer screening support, genomics, and autonomous-vehicle trials. He also said adoption should not run ahead of the country’s ability to retrain and support affected workers, that autonomous vehicles should scale only after safety is proven, and that people must remain in control as capable agents create harder-to-predict risks. The speech committed Singapore to practical safeguards at home and coalitions for international rules, while stopping short of specifying every enforcement mechanism or timetable. The value of the approach is its sequence: prove the system, govern the risk, support the people disrupted, then scale. That standard now needs measurable implementation through named regulators, published stop conditions, worker outcomes, incident disclosure, and public evidence that human control is operational rather than ceremonial.

5 min
A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters07

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
A clinical waveform and reinforcement-learning decision tree ending at an evidence gap.
Cognition & learningGlobal+2 clusters08

Tang et al., “Reinforcement learning for treatment decision-making in sepsis: a scoping review”

Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.

2 min